ADC usage in breast cancer treatment increased 3.7-fold from 2021 to 2023, with significant reductions in median time to treatment. Older women experience lower ADC treatment rates and longer delays ...
The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...
Chemotherapy drugs are well suited to killing cancer cells, but they’re bad at killing only cancer cells — the destruction of healthy tissue has been an inevitable outcome. This toxicity is why ...
Regeneron is pretty good at making antibodies. It’s kind of its thing. But, while the industry has gone deal crazy for antibody-drug conjugates (ADCs), the company has stayed out of the limelight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results